Keywords: allergan, completes, oral, tazarotene, trials, completed, phase

Allergan completes oral tazarotene trials

Article | 17 March 2003

Print This

Allergan has completed two Phase III trials of an oral formulation ofits receptor-selective retinoid drug tazarotene as a treatment for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in